Contrast agent developer Amersham Health of the U.K. has signed a deal with pharmaceutical giant Pfizer of New York City to use PET technology for drug discovery applications.
Pfizer will fund research at Amersham’s Imanet network of PET research centers, which will use PET to identify new molecular diagnostic products based on library compounds in Pfizer’s research portfolio. Amersham’s imaging technology is also expected to help accelerate research decisions.
Amersham has rights to develop and commercialize diagnostic agents that result from the collaboration. The company said it hopes to sign similar deals with other pharmaceutical firms.
By AuntMinnie.com staff writersFebruary 1, 2002
Related Reading
Amersham expands radiopharmacy network, January 23, 2002
Amersham debuts MPOptions, January 8, 2002
GE and Amersham to collaborate in PET, November 30, 2001
Bristol-Myers-Squibb, Amersham Health share patent rights, November 15, 2001
Amersham renames Nycomed Amersham Imaging, October 15, 2001
Copyright © 2002 AuntMinnie.com
